IDiyas

For the Inventor, By the Inventor

Wynnewood, PA, United States of America

Edward M Scolnick

USPTO Granted Patents = 11

Average Co-Inventor Count = 2.7

ph-index = 7

Forward Citations = 222(Granted Patents)


Location History:

  • Wyneewood, PA (US) (1991)
  • Wynnewood, PA (US) (1986 - 2001)

Company Filing History:

goldMedal11 out of 4,770 
 
Merck + Co., Inc.
 patents

Years Active: 1986-2001

Loading Chart...
11 patents (USPTO):Explore Patents
1. 6177404 - Conjugates useful in the treatment of benign prostatic hyperplasia (2001-01-23),
2. 5663195 - Method of preventing bone loss (1997-09-02),
3. 5376383 - Method for enhancing the lowering of plasma-cholesterol levels (1994-12-27),
4. 5310668 - Varicella-zoster virus as a live recombinant vaccine (1994-05-10),
5. 5258401 - Cholesterol lowering compounds (1993-11-02),
6. 4997658 - Method for enhancing the lowering of plasma cholesterol levels (1991-03-05),
7. 4952561 - Cardiac atrial peptides (1990-08-28),
8. 4851436 - HMG-CoA reductase inhibitors (1989-07-25),
9. 4707542 - Immunogenic HbsAg derived from transformed yeast (1987-11-17),
10. 4668699 - Novel HMG-CoA reductase inhibitors (1987-05-26),
11. 4614793 - Hepatitis A--subunit antigen (1986-09-30),

Title: Edward M Scolnick: Innovator in Pharmaceutical Sciences

Introduction

Edward M Scolnick is a prominent inventor based in Wynnewood, PA (US). He has made significant contributions to the field of pharmaceutical sciences, holding a total of 11 patents. His work primarily focuses on innovative treatments for various medical conditions, showcasing his dedication to improving patient care.

Latest Patents

Among his latest patents, Scolnick has developed novel pharmaceutical compositions useful for the treatment of benign prostatic hyperplasia. These compositions comprise oligopeptides that are selectively cleaved by enzymatically active PSA, in conjunction with a cytotoxic agent. Additionally, he has invented a method of preventing bone loss, which involves administering a non-toxic therapeutically effective amount of a selective cyclooxygenase-2 inhibitor. This method aims to halt or retard bone mass loss, reduce fractures, and improve bone repair.

Career Highlights

Scolnick's career is marked by his association with Merck & Company, Inc., where he has played a vital role in advancing pharmaceutical research and development. His innovative approaches have led to significant advancements in treatment methodologies, particularly in urology and bone health.

Collaborations

Throughout his career, Scolnick has collaborated with notable colleagues, including William F Hoffman and Robert L Smith. These partnerships have fostered a collaborative environment that encourages the exchange of ideas and enhances the development of groundbreaking treatments.

Conclusion

Edward M Scolnick's contributions to pharmaceutical sciences exemplify his commitment to innovation and patient care. His patents and collaborative efforts continue to influence the medical field positively.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…